Fig. 2From: Treatment benefit of upfront autologous stem cell transplantation for newly diagnosed multiple myeloma: a systematic review and meta-analysisRisk-of-bias assessment. A, C. The revised Cochrane risk-of-bias tool for randomized trials (RoB2) of the RCT studies included in the meta-analysis; B, D. The Cochrane risk of bias tool for non-randomized studies (ROBINS-I) of the observational studies in the meta-analysis. RCT, randomized controlled trialBack to article page